FMP
Summit Therapeutics Inc.
SMMT
NASDAQ
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
19 USD
0.33 (1.74%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Robert W. Duggan
sector
Healthcare
industry
Biotechnology
website
https://www.summittxinc.comexchange
NASDAQ
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cam...
CIK
0001599298
ISIN
US86627T1088
CUSIP
86627T108
Address
One Broadway
Phone
617 514 7149
Country
US
Employee
105
IPO Date
Mar 5, 2015
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
SMMT Financial Summary
CIK
0001599298
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
86627T108
ISIN
US86627T1088
Country
US
Price
19
Beta
-0.92
Volume Avg.
2.58M
Market Cap
14B
Shares
-
52-Week
2.1-33.89
DCF
-0.07
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-82.61
P/B
-
Website
https://www.summittxinc.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SMMT News
It looks like there's no news available.
